Research ArticleTissue Engineering

Safety and Efficacy of an Injectable Extracellular Matrix Hydrogel for Treating Myocardial Infarction

See allHide authors and affiliations

Science Translational Medicine  20 Feb 2013:
Vol. 5, Issue 173, pp. 173ra25
DOI: 10.1126/scitranslmed.3005503

This article has a correction. Please see:


New therapies are needed to prevent heart failure after myocardial infarction (MI). As experimental treatment strategies for MI approach translation, safety and efficacy must be established in relevant animal models that mimic the clinical situation. We have developed an injectable hydrogel derived from porcine myocardial extracellular matrix as a scaffold for cardiac repair after MI. We establish the safety and efficacy of this injectable biomaterial in large- and small-animal studies that simulate the clinical setting. Infarcted pigs were treated with percutaneous transendocardial injections of the myocardial matrix hydrogel 2 weeks after MI and evaluated after 3 months. Echocardiography indicated improvement in cardiac function, ventricular volumes, and global wall motion scores. Furthermore, a significantly larger zone of cardiac muscle was found at the endocardium in matrix-injected pigs compared to controls. In rats, we establish the safety of this biomaterial and explore the host response via direct injection into the left ventricular lumen and in an inflammation study, both of which support the biocompatibility of this material. Hemocompatibility studies with human blood indicate that exposure to the material at relevant concentrations does not affect clotting times or platelet activation. This work therefore provides a strong platform to move forward in clinical studies with this cardiac-specific biomaterial that can be delivered by catheter.


As medical management and surgical tools advance, a growing number of patients survive heart attacks. Unfortunately, many then develop heart failure (HF), for which the 5-year survival rate is only 50% (1). Thus, there is a pressing clinical need for new therapies to prevent progression of the negative left ventricular (LV) remodeling that follows myocardial infarction (MI) and leads to HF. During MI, a blockage in a coronary artery causes cell death followed by degradation of the associated extracellular matrix (ECM) and an acute inflammatory response. Owing to the limited regenerative capacity of the myocardium, the injury is resolved with formation of a dense collagenous scar. This scar cannot contribute to the pumping function of the heart, and over time, the remote myocardium hypertrophies to compensate, the infarct wall continues to thin, the ventricle dilates, and ultimately the heart fails. The only successful treatments for end-stage HF are total heart transplantation and LV assist devices; however, the former is limited by a severe lack of donor organs, the latter relies on chronic use of an external device, and both require invasive, inherently risky surgical procedures.

Experimental approaches to mitigate negative LV remodeling and prevent HF include LV restraints, cardiac patches, in situ–gelling biomaterials, and cell transplantation. Interest in LV restraints has waned considerably over the past 5 years as focus has turned toward more targeted, biodegradable strategies. Cellular cardiomyoplasty has been used experimentally in the clinic with some success, but continues to be limited by poor cell survival and retention after implantation. Scaffold biomaterials vary widely (24), and most work has shown that these materials can provide maintenance or improvement in functional parameters in small animals and some large-animal models, either alone or with cells or growth factors. However, most of these approaches will not transition to minimally invasive delivery in the clinic: Patches require a thoracotomy for epicardial placement and most existing injectable biomaterials are not compatible with cardiac catheter procedures, which require the material to be in the catheter up to 1 hour (5, 6).

ECM-based materials have emerged as a promising class of naturally derived biomaterial scaffolds. Given the tissue specificity of the ECM, it follows that the most appropriate scaffold to replace the damaged ECM after an MI would be derived from myocardial tissue. We previously developed an injectable ECM hydrogel derived from decellularized porcine myocardial tissue (7), which self-assembles into a porous and fibrous scaffold upon injection into tissue, and recently demonstrated that injecting this ECM hydrogel after MI in a rodent model mitigated LV remodeling and preserved ejection fraction (EF) (8). However, to translate this material to the clinic, we needed to address the biocompatibility and safety of this ECM-derived material and investigate its efficacy in a clinically relevant large-animal model. The biocompatibility of injectable ECM hydrogels for this application has been indirectly supported in the literature (7, 9) and the immune response to decellularized ECM grafts placed subcutaneously has been explored (10, 11), but little work has been done to explore the site-specific tissue response to these materials over an extended time course or to understand the hemocompatibility and thromboembolic potential of these materials. Moreover, large-animal studies are crucial to explore the effectiveness of an ECM-derived hydrogel for tissue repair. Here, we show that the myocardial matrix hydrogel can be used to prevent negative remodeling and HF in a clinically relevant porcine MI model and further establish the safety and biocompatibility of the material in rodent studies.


Myocardial matrix improves cardiac function and mitigates negative LV remodeling

A porcine model was used to assess the efficacy of myocardial matrix injections for treatment after MI. Two weeks after MI, transendocardial injections of a myocardial ECM–derived hydrogel (myocardial matrix) and saline were delivered to the ischemic region using a catheter traditionally used for cellular cardiomyoplasty procedures. Two pigs received no injections owing to limiting factors during the procedure. Echocardiography data showed improvements in cardiac functional parameters in the matrix-injected animals and a worsening of function in the control animals (Table 1). Parameters measured included EF, which is a measure of cardiac function, and LV end-diastolic volume (EDV) and end-systolic volume (ESV). There was no statistical difference between the two groups before MI or at 2 weeks after MI pre-injection (P > 0.05, Student’s t test). However, at the time of euthanasia (3 months after injection), the EF of the matrix group was significantly greater and their EDV and ESV were significantly smaller than those of the control animals (Table 1).

Table 1

Echocardiography data from porcine MI study. Pre-injection measurements were taken 2 weeks after MI. Pre-euthanasia measurements were taken 3 months after injection, with the exception of one control, which died 2 months after injection. Data are means ± SEM (n = 4, control; n = 6, myocardial matrix). *P < 0.01, **P < 0.05 compared to control pre-euthanasia (Student’s t test); P < 0.01, P < 0.05 compared to pre-MI (paired t test).

View this table:

Figure 1A displays individual animal data at pre-MI, pre-injection (2 weeks after MI), and pre-euthanasia (3 months after injection). One saline-injected animal was euthanized 2 months after injection. Injection of the myocardial matrix resulted in an improvement in EF in five of six animals, whereas three of four control animals worsened (Fig. 1A). EDV was decreased in 50% of the matrix-injected animals, whereas it increased in 75% of the control animals (Fig. 1A). Last, the ESV improved with myocardial matrix injection in four of six animals, whereas every control animal had increased ESV (Fig. 1A).

Fig. 1

Echocardiographic data show improvement after injection of myocardial matrix. (A) EF, EDV, and ESV are shown for each animal pre-MI, pre-injection (2 weeks after MI), and pre-euthanasia for both the control (n = 4) and matrix-injected (n = 6) groups. Control animals that received saline injections are indicated with closed circles (green and blue lines); animals that received no injection are represented with open circles (red and purple lines). (B) Comparison of the absolute changes in EF, EDV, and ESV from either pre-MI baseline or pre-injection to the time of euthanasia. (C) GWMI improves in matrix-treated animals. Note that error bars are present but not visible for the matrix-injected group at pre-euthanasia. All data are means ± SEM. *P < 0.05 versus control (Student’s t test).

As seen in control data in Fig. 1A, one animal (in green) had a larger ventricle before MI compared to other animals in the study; this contributes to the large variability in the data presented in Table 1 and makes comparisons between the two groups based solely on averages more difficult to compare. We therefore compared absolute changes in functional parameters between groups (Fig. 1B). For changes from euthanasia to pre-MI baseline values, the decline in EF and increase in EDV and ESV were significantly smaller with myocardial matrix treatment compared to controls (Fig. 1B). The change from euthanasia to pre-injection (2 weeks after MI) for the ESV of the matrix group was significantly smaller compared to controls, with similar trends toward improvement in EF and EDV (Fig. 1B).

Global wall motion index (GWMI) scores corroborated these functional data. Wall motion is scored as normal (1), hypokinetic (2), akinetic (3), or dyskinetic (4). Treated animals regained a more normal GWMI over the course of the study, whereas control animals continued to worsen (Fig. 1C). Regional dysfunction, as implied by an increased wall motion score, was similar in both groups at each time point until after treatment, at the final echo, at which point the control animals had a significantly larger average GWMI than the treated group. These data support the potential for the myocardial matrix to mitigate the negative LV remodeling observed after MI, specifically by improving systolic function and contractility.

In addition to echocardiographic measurements, electromechanical NOGA data were collected pre-injection (2 weeks after MI) and pre-euthanasia (3 months after injection) from all six matrix-injected animals and two of the control animals. Two control animals did not receive NOGA mapping owing to a clot in the LV that prevented mapping in one noninjected animal and the death of the second saline animal at 2 months. Unipolar and linear length shortening (LLS) methods were both used to calculate the change in infarct size over the course of the experiment. Representative unipolar map changes are illustrated for a control animal’s heart and a matrix-injected heart in Fig. 2A, where the red area indicates decreased conduction and is indicative of the infarct area. By the unipolar method, infarct size in matrix-injected hearts had an average fractional increase of 2.1, from 6.5 ± 2.9 cm2 to 9.3 ± 2.5 cm2, whereas infarct size in control animals had an average fractional increase of 11.0, from 2.8 ± 2.4 cm2 to 19.1 ± 11.9 cm2 (mean ± SEM) (Fig. 2B). By the LLS method, infarct size in matrix-injected hearts had a fractional decrease of 0.3, from 6.5 ± 3.1 cm2 to 4.9 ± 3.2 cm2, and infarct size in control animals had a fractional increase of 17.5, from 9.2 ± 8.7 cm2 to 16.0 ± 2.2 cm2 (Fig. 2C).

Fig. 2

NOGA mapping and infarct expansion. (A) Representative unipolar area NOGA maps taken at time of injection and euthanasia. Images are thresholded to show the cutoff (6.9 mV) for the infarct area. (B) Infarct expansion calculated by unipolar area in myocardial matrix–treated animals (n = 6) compared to the control group (n = 2). (C) Infarct expansion calculated via linear local shortening. Data are means ± SEM. *P < 0.05 (Student’s t test).

Myocardial matrix enhances cardiac muscle and reduces infarct fibrosis

At the end of the study, hearts were removed and tissue sections at the mid-infarct point were examined. The infarcted areas from the two groups showed distinct differences in endocardium morphology (Fig. 3). Masson’s trichrome staining revealed that all matrix-injected hearts had a distinct band of muscle along the endocardium (Fig. 3A). The noninjected control animals had an endocardium that appeared as a thin layer with endothelium, with a loose fibrillar layer beneath the endothelium (Fig. 3B). In saline-injected control animals, the endocardium was moderately thickened and showed minimal muscle formation (Fig. 3C). The red-stained zone was verified to be cardiomyocytes by staining adjacent slides with anti–cardiac troponin-T (Fig. 3D). The area of this endocardial muscle layer as a proportion of the total infarct size was quantified and found to be significantly larger in the matrix-injected animals compared to control animals (Fig. 3E). We also quantified the percent fibrosis in the infarct and found that matrix injection significantly reduced the percentage of collagen within the infarct compared to controls (Fig. 3F). There were also foci of neovascularization present in the area below the endocardium of all matrix-injected hearts (Fig. 3G). None of the control hearts showed similar foci of neovascularization (Fig. 3H).

Fig. 3

Histological characterization of infarcted pig hearts. (A to C) Masson’s trichrome staining images are representative of six matrix-injected pigs and four control animals. (A) Matrix-injected hearts had a distinct, thick endocardium (red stained muscle, indicated with an asterisk). (B) Noninjected control animals had a loose fibrillar layer (blue) beneath the endothelium. (C) In saline-injected control animals, the endocardium was moderately thickened with minimal muscle (red). (D) An adjacent tissue section for the matrix-injected animal in (A) stained for cardiac troponin-T, indicating the presence of cardiomyocytes. (E) Area of endocardial layer of muscle as a proportion of the infarct. (F) Percentage of collagen content in the infarcts. Data are means ± SEM and were obtained from Masson’s trichrome slides (A to C). *P < 0.05 (Student’s t test). (G and H) Matrix-injected hearts contained foci of neovascularization in the area below the endocardium (G, arrows), but none of the saline or noninjected control hearts showed these areas of neovascularization (H). Scale bar, 200 μm.

Myocardial matrix does not adversely affect peripheral tissues, cardiac rhythm, or blood chemistry in treated pigs

Tissue samples were taken from peripheral organs (kidneys, brain, spleen, liver, and lungs) of the pigs and examined by a pathologist blinded to the study groups. There were no substantial differences between the two groups. The differences that were observed were interpreted as incidental lesions that were not associated with the experimental treatments. These included mild liver lesions such as mild centrilobular congestion in one matrix-injected animal and mild multifocal mononuclear cells (lymphocytes with or without other lymphoid cells) in three matrix animals. One common lesion identified as a postmortem artifact was splenic red pulp congestion in all animals except two of the controls (fig. S1).

Electrocardiogram (ECG) data from matrix injection showed no abnormalities in rhythm or waveform morphology. No matrix injection–related effect on the heart rate or RR, PR, QRS, QT, or QTc intervals was found on the basis of comparison of pre- and post-injection values and control values (table S1). In the Holter data, infrequent short periods of nonsustained ventricular tachycardia were found in three of the matrix-injected animals. In two of the three animals, tachycardia occurred before injection of myocardial matrix; in a third animal, one period of five preventricular contractions was observed 1 week after injection (table S2). On the basis of comparison of pre- and post-injection mean ECG recordings to the control animal ECG recordings, all the ECGs were considered normal for Yucatan pigs.

Clinical laboratory assays for the matrix-injected animals were also considered normal at each time point (pre-MI, pre-injection, and pre-euthanasia), with the exception of a low fibrinogen reading (55 mg/dl) at the time of euthanasia for one animal.

Myocardial matrix is biocompatible and biodegradable

We also examined the safety and biocompatibility of the myocardial matrix using rodents and human blood samples. Healthy rats received intramyocardial injections of decellularized porcine myocardial matrix (PMM), saline, or a nondecellularized porcine myocardial matrix (NDM) and then were euthanized for histological evaluation after 1, 3, 7, 14, 28, 56, or 112 days (n = 2–6 per time point per group). The PMM was identifiable in tissue sections on days 1, 3, and 7. In one of two hearts evaluated, PMM was still present at 14 days but was completely degraded in all three hearts by 28 days (Fig. 4). On average, the lesion area per slide in NDM-injected animals was 48% larger than the lesion area in PMM-injected animals (0.66 ± 0.17 μmm2 versus 0.97± 0.31 μmm2) and 52% larger than that in saline-injected animals (0.64 ± 0.13 μmm2) (mean ± SEM). Initially, the inflammation in PMM-injected animals was overall greater than that in saline-injected animals; however, both were resolved at 56 and 112 days.

Fig. 4

Cell infiltration in matrix-injected rat hearts. Representative histological sections from rat hearts injected with saline, PMM, or NDM at days 3, 14, and 28. Inflammation and multinucleated giant cells are present in the NDM groups at days 14 and 28 (arrows). The PMM (asterisk-marked porous network) was completely degraded by 28 days. Scale bar, 200 μm.

Cellularity of the injected areas was assessed using a scoring system where cell infiltration was either absent (0), minimal (1), mild (2), moderate (3), or marked (4). These scores did not take the size of the lesion into consideration but rather the degree to which the cell type was represented in the cell infiltrate. Thus, when two groups have similar scores, it is a reflection that they have similar composition of infiltrating cells, not that the overall degree of inflammation is the same. NDM-injected animals had lesions that were higher in cellularity and area over the entire course of the study. In all groups, there was an acute inflammatory response characterized by an early peak in infiltrating polymorphonuclear cells (PMNs) that decreased over time (Fig. 5A). Lymphocytes were a dominant cell type in the NDM group but appeared to a lesser degree in the saline and PMM groups (Fig. 5B). Large mononuclear cells (macrophages) were present during inflammation in all groups, although they were more dominant in the NDM group at early time points compared to the saline and PMM groups (Fig. 5C). Spindle cells (fibroblasts, myofibroblasts, and cardiomyocytes) became dominant cell types in the saline- and PMM-injected groups after 2 weeks (Fig. 5D), indicating a reparative response. Signs of chronic inflammation, including multinucleated giant cells, were only observed in the NDM group (Fig. 5E) and not in the PMM- or saline-injected group (Figs. 4 and 5E). Given the semiquantitative nature of these data, statistical analysis was not performed. These cell infiltration data demonstrate the biocompatible nature of the myocardial matrix when appropriately processed (decellularized) to remove the cellular content.

Fig. 5

Matrix biocompatibility assessment in rats. (A to E) Average score for infiltration and degree of inflammation with respect to PMNs (A), lymphocytes (B), large mononuclear cells (C), spindle cells (fibroblasts, myofibroblasts, and cardiomyocytes) (D), and multinucleated giant cells (E). On this scale, 0 = absent, 1 = minimal, 2 = mild, 3 = moderate, and 4 = marked. Note: no animal experiments were performed for NDM at day 7.

Matrix injection does not cause embolization or ischemia

The second approach to verifying the safety of this treatment was via direct injection into the LV lumen in rats. Leakage can occur with transendocardial injection, so it is important to understand the hemocompatibility and thromboembolic potential of the material in the event that the material enters systemic circulation. Rats that received direct injections of myocardial matrix (n = 4) or saline (n = 2) into the lumen of the LV were revived and observed for 6 hours. All rats recovered normally and showed no signs of stress or discomfort before euthanasia. Histological examination of kidneys, heart, brain, spleen, liver, and skeletal muscle found no signs of acute ischemia or thrombus, and the degree of edema, hemorrhage, and inflammation was minimal and not different between groups. There was a moderate degree of edema and inflammation in the lungs, but it was similar between saline- and matrix-injected animals and attributed to trauma associated with the surgery (fig. S2).

Human blood tests show hemocompatibility of myocardial matrix

We examined the interaction between the injected matrix and human blood with respect to clotting times and platelet activation. Myocardial matrix was evaluated at different concentrations in blood. The “standard” concentration reflected a conservative estimate of the amount of matrix that would be injected into the bloodstream if the needle disengaged from the endocardium. Addition of the myocardial matrix to human plasma had no effect on activated partial thromboplastin time (APTT) or prothrombin time (PT) (Table 2). At both the standard concentration (volume ratio, 1:10,000) and a higher concentration (1:2500), APTT and PT remained within reference ranges (Table 2).

Table 2

Clotting times after exposure to myocardial matrix. The PT and the APTT were obtained for human plasma samples after the addition of saline (control), the myocardial matrix at a standard concentration (1:10,000), and the myocardial matrix at a high concentration (1:2500). Data are means ± SEM (n = 2).

View this table:

Additionally, exposure of platelet-rich plasma (PRP) to myocardial matrix at standard estimates did not cause platelet activation, as indicated by a constant turbidity (Fig. 6). At a “high” concentration (2.5 times the standard concentration, or volume ratio 1:4000), minimal platelet activation was observed, as indicated by the dip in turbidity after 3 min (Fig. 6B). The addition of agonists after 5 to 10 min resulted in normal platelet activation, as indicated by the sharp decrease in turbidity (Fig. 6, A and B). After 4 hours, the quality of the sample was verified by adding agonists directly to time-matched control PRP samples and observing normal activation curves (Fig. 6C).

Fig. 6

Platelet activation. (A and B) Addition of myocardial matrix to human PRP was done at a standard concentration (1:10,000) (A) and a high concentration (1:4000) (B), and the samples were evaluated for at least 5 min. After the samples plateaued, agonists were added (at 5 to 10 min). (C) A control was performed after 4 hours to ensure normal activity of the samples and validity of the data in response to agonists. Data shown are representative traces from four repeated experiments. ADP, adenosine diphosphate; AA, arachidonic acid.


Confirming the success of previous small-animal work (8), this study demonstrates efficacy and feasibility in a clinically relevant porcine MI model, where both the pathophysiology and the administration mimic what would be observed and performed in humans, as well as addresses important remaining safety issues. Here, we demonstrate the potential for an injectable myocardial matrix hydrogel to improve cardiac function, prevent negative LV remodeling, and increase cardiac muscle after MI in a porcine model.

Decellularized matrix materials have been used as “nature’s platform” for a variety of tissue regeneration applications, including the whole heart (12), and injectable hydrogels derived from small intestinal submucosa and pericardium have been both investigated for cardiac repair in rodent models (13, 14). Because the ECM is specific to each tissue, the myocardial ECM can potentially provide appropriate tissue-specific cues for infiltrating cells. In vitro, biochemical cues from the myocardial matrix have been shown to promote maturation of human embryonic stem cells (15) and cardiac differentiation and survival of cardiac progenitor cells (16). It is known that there are more cardiac progenitor cells in failing hearts (17); thus, by mitigating the harsh infarct milieu, the injected matrix may also provide a more appropriate environment as well as a physical scaffold for circulating stem cells to encourage repair and regeneration (8). In the rat MI model, we observed larger clusters of cardiomyocytes in the infarct area at 1 week after injection, which we postulated was a result of improved cardiomyocyte survival (8). In the porcine model, we observed a significantly larger area of cardiac muscle accompanied by areas of neovascularization at the endocardium 3 months after injection in treated animals compared to control animals. This may be a combination of preserved cardiomyocytes and newly formed cardiomyocytes because we previously observed proliferative cardiac troponin-T+ cells and c-kit+ cells within the matrix in the rat MI (8). This also suggests that the myocardial matrix contributes to improvements in contractility by increasing a layer of muscle at the endocardium, which is where the biomate rial is delivered. Injection of other materials, such as peptide nanofibers, has also shown newly formed cardiomyocyte-like cells, but co-delivery with a growth factor (vascular endothelial growth factor) was required (18). Here, the material alone increased cardiac muscle and improved contractility.

There are several important design considerations that must be met for injectable biomaterials to be useful and relevant treatments for MI. One that is crucial to clinical translation is the delivery method. Although several injectable biomaterials have shown promising results in small animals, few have been translated to percutaneous delivery in large animals. To date, the only other material to be delivered percutaneously in a large-animal MI model is alginate (19). Leor et al. demonstrated success with intracoronary infusion of alginate in preclinical work in swine (19), which led to delivery in a small phase 1/2 study in acute MI patients ( identifier NCT00557531) and an ongoing phase 2 clinical trial (NCT01226563). The myocardial matrix is the second material to be delivered percutaneously in a large MI model and the first material to be delivered via a transendocardial approach. Transendocardial delivery is considered by many to be the preferred method of catheter delivery (2022). This method allows for guided, direct intramyocardial delivery, which increases biomaterial retention and does not require access to the coronary vessels, reducing the risk of embolization. Additionally, the coronary access required for intracoronary delivery is often compromised in the target patient population. Here, we chose to inject 2 weeks after MI, the same time point we previously used rats (8). Injection is generally considered risky in the clinic in the first week after MI because of the potential for ventricular rupture due to the unstable ventricular wall caused by matrix metalloproteinase up-regulation. Moreover, injection immediately after MI would likely cause premature degradation of our ECM-derived scaffold at the same time the native ECM is being degraded.

Echocardiographic GWMI, which is a measure of regional function, has been shown to be a significant predictor of cardiovascular death after acute MI and has independent prognostic value when added to a model that includes EF and other baseline clinical values (23, 24). The reduction in this parameter in matrix-injected animals implies improvement in regional function and contractility. In addition to the enhanced GWMI and EF in the matrix-injected animals, LV volumes also demonstrated an improvement. In HF patients, increases in ESV indicate a decline in contractility. This pattern is observed in the controls, where the LV ESV continues to increase after MI. The matrix group, however, had on average a decreased ESV compared to the controls. This implies that the myocardial matrix may provide a method for preventing the negative remodeling of the ventricle that precedes HF and for improving systolic function, potentially through the increase in cardiac muscle observed at the endocardium. We found improvements in global and regional cardiac function and LV volumes, whereas alginate, the only other material to be delivered percutaneously in a large MI animal model, significantly changed LV geometry but not fractional shortening (19). Other hydrogels alone, such as fibrin-alginate (25), hyaluronic acid (26), and peptide nanofibers (27), which have been delivered in large animals using direct injection (noncatheter-based), have likewise not improved EF. Our data also supported safety with respect to the effect on cardiac electrophysiology. Ectopic beats and QRS changes were seen as a result of the infarction procedure in both the matrix-injected and control animals; no additional abnormalities occurred as a result of the injection.

Evaluation of the local tissue response to decellularized ECM biomaterials injected in the myocardium has not been described previously. Performing this study in rats allowed us to evaluate the material in a xenogeneic model. The increased presence of spindle cells, which include fibroblasts, myofibroblasts, and cardiomyocytes, observed in the matrix group supports a reparative remodeling response. This is corroborated by the cardiomyocyte populations identified in the infarcts of matrix-injected pigs. Signs of chronic inflammation—persistent lymphocyte presence and the appearance of multinucleated giant cells—were only observed in the nondecellularized control. This implies that the response to cellular debris is more severe and may be associated with rejection or a foreign body response, rather than the remodeling response seen with decellularized matrix materials, which is consistent with previous work with decellularized grafts (28). Here, we show degradation of the matrix between 14 and 28 days and an appropriate inflammatory response that may promote remodeling. Here, we used only porcine-derived matrix because this is the most viable source as a clinical product because human tissue has greater variability and collection of healthy human hearts is limited; many porcine-derived ECMs are also already approved by the U.S. Food and Drug Administration (29).

An important criterion for translation is lack of thrombogenicity, and in this work, we demonstrate myocardial matrix to be nonthrombogenic upon direct injection into the LV lumen. The lack of post-procedural distress in rats indicated no major event, and we found no difference in tissue morphology in peripheral organs in both matrix- and saline-injected animals. These findings are supported by a similar lack of significant findings in the tissue analyzed from the pigs in the large-animal study. When injected directly into the LV lumen, myocardial matrix is immediately diluted upon injection into the bloodstream and therefore likely does not have a chance to self-assemble and is quickly degraded and cleared. In contrast, a synthetic or naturally derived biomaterial that gels very quickly or causes protein aggregation could cause detrimental clot formation in the LV or peripheral vasculature (30).

In addition to thrombogenicity of an injected material, it is also essential to understand potential interactions between the matrix and the host blood. Clotting times are an important clinical parameter, especially for patients under medical management for cardiovascular diseases. Here, the matrix was shown to be hemocompatible in human blood because there was no change in clotting times with the addition of the material and no platelet activation with the addition of the standard material concentration. The slight activation observed with the high concentration of myocardial matrix is expected, because collagen is a significant component of ECM hydrogels (8) and an agonist; the observed level of activation is, however, not considered clinically relevant.

Although the data generated support the efficacy and safety of this biomaterial therapy, there are limitations to this work. For example, a conventional pharmacologic regimen was not used, such as angiotensin-converting enzyme inhibitors or β blockers. Additionally, the pig numbers were small, with the four controls in the porcine functional study combining both saline injection and no injection. Although this study would have been strengthened by more saline-injected animals, previous work with this porcine MI model has shown that cell growth medium–injected control animals similarly declined after injection (31), which corroborates our control data. Additionally, similar animal numbers per group have been used in large-animal preclinical MI studies that have been deemed sufficient to initiate clinical trials (19, 31, 32). These previous studies examined cardiac function out to 2 months after MI, whereas we examined functional parameters out to 3 months after injection, which is well beyond the material degradation time of 2 to 3 weeks. Despite a low number of control animals, the functional changes seen in the cardiac functional data within the matrix-treated group are promising, particularly the improved ESV, which is considered to be the best clinical predictor of survival after MI (33, 34), as well as improved regional contractility as indicated by the improved GWMI.

In summary, we have established the safety and efficacy of an injectable myocardial matrix biomaterial in preclinical large- and small-animal studies. This work, taken in conjunction with previous small-animal studies with the same material (8), provides support for the advancement of this technology from preclinical studies to clinical trials.

Materials and Methods

Preparation of injectable ECM hydrogels

Ventricular porcine myocardium was decellularized with SDS and processed into an injectable ECM hydrogel via lyophilization and partial pepsin digestion (7, 8). Decellularization and ECM preparation protocols can be found in the Supplementary Materials and Methods. NDM was prepared according to the same protocols (Supplementary Materials and Methods) except that the fresh tissue was frozen, lyophilized, milled, and digested without decellularization.

Porcine procedures

All experiments were performed in accordance with the guidelines published by the Institutional Animal Care and Use Committee at the University of California, San Diego, and the Association for the Assessment and Accreditation of Laboratory Animal Care International.

MI was induced in mature Yucatan mini-pigs (45 to 50 kg) via the percutaneous coil embolism infarct model, as developed and validated by Dib et al. (31, 35). Before MI, a 12-lead ECG and echocardiogram were obtained to ensure that the animal was healthy. On each animal, a sheath was inserted into either the right or the left femoral artery, allowing catheter access to the artery and retrograde access to the LV through the aorta. The anesthesia protocol is detailed in the Supplementary Materials and Methods.

MI was induced by the deployment of one to two complex helical fibered platinum coils (Boston Scientific) within the left anterior descending coronary artery. If the first coil did not occlude the artery, a second coil was deployed. After each coil deployment, the ECG was monitored for changes, and ST elevation was considered to be indicative of occlusion. Post-MI angiograms were performed to confirm arterial occlusion. Animals were carefully monitored until fully recovered from anesthesia. Resuscitation via electrical cardioversion (360 J) was administered if the animal experienced sustained ventricular tachycardia.

About 2 weeks after MI (12 to 14 days), myocardial matrix or saline was injected into the infarct area via percutaneous transendocardial delivery. Anesthesia was administered as in the MI procedure, described in the Supplementary Materials and Methods. Arterial access was gained on either the left or the right femoral artery, and a NOGA map was created in the endocardial wall to identify the infarcted region. A Biosense Webster Type B injection catheter was used for injections, and its needle length in the straight and curved position was adjusted to be 3.5 mm straight. The injection catheter was flushed with myocardial matrix before insertion. The NOGA map was used to guide injections throughout the infarct and border zone. Fresh material was pulled up into a new 1-ml syringe for each set of injections to allow for 14 to 15 injections of 0.25 ml for a total of 3.5 to 3.75 ml in each animal. Animals were recovered and euthanized 3 months after injection. NOGA mapping was repeated before euthanasia. The infarct area was determined as the area below 6.9 mV and 6% on the unipolar and LLS maps, respectively (36). ECGs, Holter monitoring, echocardiography, and angiography methods are described in the Supplementary Materials and Methods. Animals were fasted overnight before each surgical procedure (MI, injection, and euthanasia), and blood draws were performed from femoral access under anesthesia.

Of the 14 infarcted pigs, 2 died within 24 hours of the MI procedure, 6 received myocardial matrix injections, 2 received saline injections, and 2 received no injections owing to limiting factors during the procedure (thrombus in the LV that prevented visualization of the endocardial border and complications in the placement of the catheter sheath that prevented use of the injection catheter). One pig in the saline-injected group was euthanized after 2 months because of suffering caused by the infarct; data from this animal are included. One pig in the saline-injected group was identified as having hypertrophic cardiomyopathy upon euthanasia and examination of the pre-MI echocardiogram; data from this animal were excluded. The first pig in the myocardial matrix–injected group died 24 hours after injection. This animal was the only surviving pig to require multiple electrical cardioversions as a result of sustained ventricular tachycardia during the MI procedure, and had the lowest EF of all animals pre-injection. The only notable finding upon necropsy of this pig was multifocal thromboemboli and associated parenchymal changes (congestion and atelectasis) plus pulmonary venule and small vein luminal neutrophilia in the lungs, which is likely associated with the induced MI. Although it cannot be conclusively ruled out, matrix injection was unlikely to result in this pathology given that any leakage from injections would go into the arterial bloodstream.

Animals from which data were collected for this study include six myocardial matrix–injected animals and four control animals (two saline-injected, two not injected). Unless otherwise specified, all “control group” data presented in this study are from these four animals.

Small-animal surgery protocol

Female Sprague-Dawley rats (225 to 250 g) were anesthetized with 5% isoflurane and then maintained at 2.5% isoflurane for the remainder of the procedure. Using aseptic technique, we performed injections into the LV free wall, following a well-described protocol (37). Briefly, animals were placed in supine position and an incision was made from the xyphoid process along the abdomen. A small incision was made in the diaphragm to access the apex of the heart. Samples of NDM, PMM, or saline (75 μl) were drawn up into a syringe and injected into the LV free wall through a 30-gauge needle. On days 1, 3, 7, 14, 28, 56, and 112 after injection, two to six animals per group were euthanized with the exception of the NDM group, which did not include day 7 animals.

For the direct injection safety study, 75 μl of PMM or saline was injected directly into the lumen of the LV. The animals were revived and maintained for 6 hours after the procedure and before euthanasia. After an intraperitoneal injection of 400 μl of FatalPlus (Vortech Pharmaceuticals), the animals were perfused with phosphate-buffered saline followed by 10% buffered formalin. After perfusion, the following organs were removed for histological analysis: spleen, brain, lung, heart, kidneys, liver, and skeletal muscle.

Histological analyses

For the direct lumen–injected rats and all pigs, tissue was fixed, paraffin-embedded, and then sectioned. For the biocompatibility study, hearts were fresh-frozen and cryosectioned. All tissues were analyzed in a blinded fashion by experienced pathologists (K.G.O. and G. J. Kolaja, Balboa BioConsulting Inc.).

Hematoxylin and eosin (H&E)–stained sections from direct lumen–injected rats were examined for evidence of acute ischemia, edema, hemorrhage, and inflammation in each organ. In the biocompatibility study, three H&E-stained slides representing the largest portion of the affected region from each rat heart were evaluated with a single score per animal (absent = 0, minimal = 1, mild = 2, moderate = 3, marked = 4) with respect to infiltrating multinucleated giant cells, PMNs, lymphocytes, large mononuclear cells, and spindle cells.

For the pig hearts, sections (one H&E, one Masson’s trichrome) representing the mid-infarct were analyzed. Additionally, immunohistochemistry was used to identify cardiac-specific troponin-T+ cells (Pierce, 1 μg/ml); a horseradish peroxidase–conjugated secondary antibody and metal-enhanced diaminobenzidine substrate (Thermo Scientific Pierce) were used for visualization. Slides were counterstained with hematoxylin. AxioVision software was used to outline the infarct area, and an automated program was written to count blue pixels (positive for collagen) within that region in trichrome images. The red-stained tissue near the endocardium was outlined, and the area of that tissue was compared to the total infarct area; troponin-T staining in adjacent slides was used to identify this tissue as cardiac muscle.

Statistical analysis

All data generated in the pig functional study were compared with either a paired t test or a Student’s t test. Data are means ± SEM. Significance was considered to be P < 0.05.

Supplementary Materials

Materials and Methods

Fig. S1. Histological assessment of peripheral organs in porcine study.

Fig. S2. Histological assessment of lungs in small-animal safety study.

Table S1. Quantitative averages of Holter monitoring data.

Table S2. Qualitative comparison of Holter monitoring data.

References and Notes

  1. Acknowledgments: We thank the Animal Care Program veterinary staff, particularly M. Hardee, A. Smith, J. Fujimoto, and K. Jenne (University of California, San Diego), for their understanding and expertise in the animal handling, Holter monitoring, euthanasia, and care. We also thank C. Luo for his assistance during the porcine procedures, G. J. Kolaja for his expertise in histological analysis, and P. Chamberlin for facilitating the porcine histological and Holter analysis. Additionally, we thank Biosense Webster for providing the NOGA mapping technology. Funding: This work was supported by the Wallace H. Coulter Foundation (Miami, FL), the NSF (101442), and the NIH (1R43HL108459-01A1 and 1R01HL113468-01A1). S.B.S.-N. held a graduate research fellowship from the NSF. Author contributions: K.L.C., A.M.K., and N.D. obtained the funding. K.L.C., A.N.D., and N.D. designed the porcine experiments. S.B.S.-N. designed and executed all small-animal work and wrote the manuscript. J.M.S., M.A.S., K.B., K.G.O., A.N.D., and N.D. performed the porcine studies. P.J.S.-M. and R.L.B. performed all small-animal surgeries. The acquisition and/or analysis of data was handled by S.B.S.-N., M.A.S., K.G.O., J.J.W., J.A.D., U.S., O.L.K., G.M.S., J.W., A.N.D., and N.D. Drafting and/or revising the manuscript for critical content was executed between by K.L.C., S.B.S.-N., J.A.D., J.M.S., K.G.O., and M.A.S. Administrative, technical, or supervisory tasks were handled by K.L.C., K.B., A.M.K., N.D., A.N.D., and M.P. Competing interests: K.L.C., A.M.K., A.N.D., N.D., J.A.D., and M.A.S. are equity holders; K.L.C. and A.M.K. are board members; and A.N.D. and N.D. are on the scientific advisory board of Ventrix, Inc. J.M.S., J.A.D., K.L.C., and A.M.K. are inventors on patent applications (US20120156250 and US20110189140) associated with this work and owned by the University of California, San Diego. Data and materials availability: Full pathology report of animal tissues is available upon request.
View Abstract

Stay Connected to Science Translational Medicine

Navigate This Article